

Ulrike Bacher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1807334/publications.pdf>

Version: 2024-02-01

142
papers

3,111
citations

236925

25
h-index

197818

49
g-index

148
all docs

148
docs citations

148
times ranked

4365
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160. | 3.5 | 10 |
| 2 | Oral and Subcutaneous Anticancer Therapy Training Course for Non-physician Healthcare Professionals: a Survey Evaluating the Relevance of its Content and its Implications in the Practice of Cancer Care. <i>Journal of Cancer Education</i> , 2022, 37, 120-127. | 1.3 | 0 |
| 3 | Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847. | 5.2 | 5 |
| 4 | Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357. | 5.2 | 35 |
| 5 | Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 224-231. | 2.4 | 5 |
| 6 | Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era. <i>Hematological Oncology</i> , 2022, 40, 292-296. | 1.7 | 6 |
| 7 | Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404. | 7.1 | 32 |
| 8 | Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology. <i>Current Oncology</i> , 2022, 29, 766-776. | 2.2 | 1 |
| 9 | Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients.. <i>Transplantation and Cellular Therapy</i> , 2022, , . | 1.2 | 3 |
| 10 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10. | 1.2 | 3 |
| 11 | Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML. <i>Cancers</i> , 2022, 14, 1024. | 3.7 | 5 |
| 12 | sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1463-1471. | 2.4 | 14 |
| 13 | Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy. <i>RMD Open</i> , 2022, 8, e002166. | 3.8 | 15 |
| 14 | Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1010-1012. | 2.4 | 6 |
| 15 | Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 374.e1-374.e9. | 1.2 | 4 |
| 16 | Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial. <i>Bone Marrow Transplantation</i> , 2022, 57, 990-997. | 2.4 | 8 |
| 17 | Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. <i>Cancers</i> , 2022, 14, 2516. | 3.7 | 15 |
| 18 | BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3748. | 2.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9. | 1.2 | 15 |
| 20 | Role of preâ€transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML. <i>European Journal of Haematology</i> , 2021, 106, 606-615. | 2.2 | 12 |
| 21 | Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation. <i>Hematological Oncology</i> , 2021, 39, 97-104. | 1.7 | 7 |
| 22 | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. <i>Cancers</i> , 2021, 13, 581. | 3.7 | 12 |
| 23 | When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1026. | 2.4 | 6 |
| 24 | Risk stratification systems for allogeneic haematopoietic stem-cell transplantation. <i>Lancet Haematology</i> , 2021, 8, e166-e167. | 4.6 | 0 |
| 25 | Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117. | 2.4 | 6 |
| 26 | Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers. <i>Cancers</i> , 2021, 13, 2917. | 3.7 | 4 |
| 27 | Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2021, 13, 3296. | 3.7 | 4 |
| 28 | Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML. <i>Cancers</i> , 2021, 13, 3190. | 3.7 | 5 |
| 29 | Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8092. | 4.1 | 5 |
| 30 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10. | 1.2 | 11 |
| 31 | Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12. | 1.2 | 15 |
| 32 | An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077. | 2.4 | 13 |
| 33 | Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. <i>Lancet Rheumatology</i> , 2021, 3, e789-e797. | 3.9 | 179 |
| 34 | Enhanced Immune Reconstitution of Î³Î´ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 841-850. | 1.2 | 13 |
| 35 | CAR T-cell therapy and critical care. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1318-1325. | 1.9 | 18 |
| 36 | Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland. , 2021, 3, e0552. | | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021012. | 1.3 | 5 |
| 38 | Management of transthyretin amyloidosis. <i>Swiss Medical Weekly</i> , 2021, 151, w30053. | 1.6 | 7 |
| 39 | Diagnostic and Prognostic Implications of Caspase-1 and PD-L1 Co-Expression Patterns in Myelodysplastic Syndromes. <i>Cancers</i> , 2021, 13, 5712. | 3.7 | 6 |
| 40 | Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. <i>Cancers</i> , 2021, 13, 6073. | 3.7 | 15 |
| 41 | Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479. | 2.0 | 21 |
| 42 | Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1690-1693. | 2.4 | 10 |
| 43 | Simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 74-81. | 1.7 | 8 |
| 44 | Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 268-274. | 2.8 | 8 |
| 45 | Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757. | 5.2 | 14 |
| 46 | (2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 2842. | 3.7 | 6 |
| 47 | Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820. | 1.3 | 7 |
| 48 | Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. <i>Experimental Hematology</i> , 2020, 88, 7-14.e3. | 0.4 | 21 |
| 49 | Systemic mastocytosis with an associated hematological neoplasms: One or two entities?. <i>EJHaem</i> , 2020, 1, 353-355. | 1.0 | 1 |
| 50 | Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190. | 5.2 | 18 |
| 51 | A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146. | 2.0 | 14 |
| 52 | A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, . | 6.0 | 5 |
| 53 | Experiences with next-generation sequencing in relapsed acute myeloid leukemia: a patient case series. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020068. | 1.3 | 2 |
| 54 | Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e9-e12. | 3.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973. | 5.2 | 63 |
| 56 | Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338. | 3.5 | 23 |
| 57 | Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011. | 7.1 | 39 |
| 58 | Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels. <i>Hematological Oncology</i> , 2020, 38, 523-530. | 1.7 | 12 |
| 59 | Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. <i>Nature Medicine</i> , 2020, 26, 1459-1467. | 30.7 | 122 |
| 60 | The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143. | 2.0 | 13 |
| 61 | MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation. <i>Leukemia Research</i> , 2020, 89, 106296. | 0.8 | 18 |
| 62 | A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2047-2051. | 2.4 | 6 |
| 63 | Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 425-431. | 1.7 | 8 |
| 64 | Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287. | 4.1 | 17 |
| 65 | Current concepts and future directions for hemato-oncologic diagnostics. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102977. | 4.4 | 14 |
| 66 | Survey on Recommended Health Care for Adult Patients with Myelodysplastic Syndromes Identifies Areas for Improvement. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9562. | 2.6 | 3 |
| 67 | Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. <i>Swiss Medical Weekly</i> , 2020, 150, w20364. | 1.6 | 10 |
| 68 | Correlation between the Degree of Bone Marrow Involvement and the Results of NGS in Plasma Cell Neoplasms. <i>Blood</i> , 2020, 136, 9-10. | 1.4 | 0 |
| 69 | High-Dose Chemotherapy with Bendamustine and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone. <i>Blood</i> , 2020, 136, 39-40. | 1.4 | 0 |
| 70 | Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155. | 7.0 | 10 |
| 71 | Autologous stem cell transfusions on multiple days in patients with multiple myeloma—Does it matter?. <i>Hematological Oncology</i> , 2019, 37, 649-651. | 1.7 | 2 |
| 72 | Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries. <i>Cancer Epidemiology</i> , 2019, 59, 51-57. | 1.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868. | 2.0 | 58 |
| 74 | What role can next-generation sequencing play in myelodysplastic syndrome care?. <i>Expert Review of Hematology</i> , 2019, 12, 379-382. | 2.2 | 6 |
| 75 | Clinical value of molecular MRD monitoring by next-generation sequencing in patients with <i>IDH2</i> mutated AML. <i>Leukemia and Lymphoma</i> , 2019, 60, 2588-2590. | 1.3 | 3 |
| 76 | Critical evaluation of current molecular MRD strategies including NGS for the management of AML patients with multiple mutations. <i>Hematological Oncology</i> , 2019, 37, 319-322. | 1.7 | 7 |
| 77 | High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1923-1925. | 2.4 | 14 |
| 78 | Improved survival rates of AML patients following admission to the intensive care unit. <i>Leukemia and Lymphoma</i> , 2019, 60, 2423-2431. | 1.3 | 6 |
| 79 | Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1779. | 3.7 | 20 |
| 80 | Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients. <i>HemaSphere</i> , 2019, 3, e176. | 2.7 | 4 |
| 81 | Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients. <i>HemaSphere</i> , 2019, 3, e180. | 2.7 | 5 |
| 82 | Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 511-514. | 1.3 | 13 |
| 83 | How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach. <i>Blood</i> , 2019, 134, 2457-2457. | 1.4 | 0 |
| 84 | A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients. <i>Blood</i> , 2019, 134, 1963-1963. | 1.4 | 0 |
| 85 | Rebound Thrombocytosis after Induction Chemotherapy Is a Strong Biomarker for Favorable Outcome in AML Patients. <i>Blood</i> , 2019, 134, 5101-5101. | 1.4 | 0 |
| 86 | Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?. <i>Blood</i> , 2019, 134, 3252-3252. | 1.4 | 0 |
| 87 | Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. <i>Blood Cancer Journal</i> , 2018, 8, 28. | 6.2 | 19 |
| 88 | <i>In Situ</i> Validation of the Endothelial Cell Receptor GRP78 in a Case of Rhinocerebral Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 3.2 | 15 |
| 89 | Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 64-79. | 4.4 | 12 |
| 90 | Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551. | 4.1 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. <i>Hematological Oncology</i> , 2018, 36, 436-444. | 1.7 | 13 |
| 92 | Coincidence of 5q deletion and the <i>JAK2</i>V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature. <i>Leukemia and Lymphoma</i> , 2018, 59, 2233-2237. | 1.3 | 0 |
| 93 | Current status and trends in the diagnostics of AML and MDS. <i>Blood Reviews</i> , 2018, 32, 508-519. | 5.7 | 35 |
| 94 | Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 276-281. | 2.0 | 16 |
| 95 | Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733. | 2.0 | 71 |
| 96 | Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. <i>Blood Cancer Journal</i> , 2018, 8, 113. | 6.2 | 90 |
| 97 | Autologous Transplantation for Older Adults with AML. <i>Cancers</i> , 2018, 10, 340. | 3.7 | 16 |
| 98 | Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia. <i>Transfusion</i> , 2018, 58, 2365-2373. | 1.6 | 10 |
| 99 | Platelet Transfusion Induces Alloimmunization to D and Non-D Rhesus Antigens. <i>Transfusion Medicine and Hemotherapy</i> , 2018, 45, 167-172. | 1.6 | 19 |
| 100 | Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. <i>Hematological Oncology</i> , 2018, 36, 671-678. | 1.7 | 10 |
| 101 | Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e486-e488. | 3.5 | 11 |
| 102 | Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. <i>Hematological Oncology</i> , 2018, 36, 576-583. | 1.7 | 8 |
| 103 | Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial. <i>Blood</i> , 2018, 132, 2680-2680. | 1.4 | 16 |
| 104 | Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 4358-4358. | 1.4 | 0 |
| 105 | Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 971-979. | 2.0 | 16 |
| 106 | Mutational profiling in patients with MDS: Ready for every-day use in the clinic?. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 32-42. | 1.7 | 23 |
| 107 | Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803. | 2.0 | 73 |
| 108 | Allotransplantation for Patients Age ≥ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968. | 2.0 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. <i>Blood</i> , 2012, 119, 4719-4722. | 1.4 | 62 |
| 110 | Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. <i>Blood</i> , 2012, 120, 4256-4262. | 1.4 | 128 |
| 111 | Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S62-S73. | 2.0 | 17 |
| 112 | <i>TET2</i> deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by <i>TET2</i> mutations on the remaining allele. <i>British Journal of Haematology</i> , 2012, 156, 67-75. | 2.5 | 27 |
| 113 | Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. <i>Leukemia Research</i> , 2012, 36, 826-831. | 0.8 | 14 |
| 114 | Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia. <i>Scientific World Journal</i> , The, 2011, 11, 310-319. | 2.1 | 24 |
| 115 | Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells. <i>Haematologica</i> , 2011, 96, 1284-1292. | 3.5 | 44 |
| 116 | Ganglioneuroblastoma infiltrating the bone marrow in an adult. <i>British Journal of Haematology</i> , 2011, 153, 544-544. | 2.5 | 1 |
| 117 | Deferasirox (Exjade®) Given During Conditioning Regimen (FLAMSA/Busulfan/ATG) Reduces the Appearance of Labile Plasma Iron in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 3023-3023. | 1.4 | 5 |
| 118 | Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2011, 118, 501-501. | 1.4 | 1 |
| 119 | Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 148-148. | 1.4 | 16 |
| 120 | EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/PICALM-MLLT10 Positive Acute Leukemias,. <i>Blood</i> , 2011, 118, 3440-3440. | 1.4 | 0 |
| 121 | Measurement of Liver Iron Concentration by Quantum Interference Device Biosusceptometry (SQUID) Validates Serum Ferritin As Prognostic Parameter for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1018-1018. | 1.4 | 0 |
| 122 | Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course,. <i>Blood</i> , 2011, 118, 3796-3796. | 1.4 | 0 |
| 123 | Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 4467-4467. | 1.4 | 0 |
| 124 | Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularly Defined Unique Entity. <i>Blood</i> , 2011, 118, 1443-1443. | 1.4 | 4 |
| 125 | Donor Choice for Allogeneic Stem Cell Transplantation for AML – A Retrospective Single Centre Long-Term Analysis,. <i>Blood</i> , 2011, 118, 4147-4147. | 1.4 | 0 |
| 126 | Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients. <i>Blood</i> , 2011, 118, 3024-3024. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups,. Blood, 2011, 118, 3583-3583. | 1.4 | 1 |
| 128 | Chimerism studies with quantitative real-time PCR in stem cell recipients with Acute myeloid leukemia. Experimental Hematology, 2010, 38, 1261-1271. | 0.4 | 32 |
| 129 | Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Experimental Hematology, 2009, 37, 135-142. | 0.4 | 66 |
| 130 | Current status of gene expression profiling in the diagnosis and management of acute leukaemia. British Journal of Haematology, 2009, 145, 555-568. | 2.5 | 20 |
| 131 | Induction Chemotherapy Followed Immediately by Busulfan-Based Reduced Conditioning and Allografting in Elderly Patients with Advanced MDS or sAML.. Blood, 2009, 114, 3387-3387. | 1.4 | 2 |
| 132 | Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.. Blood, 2009, 114, 1201-1201. | 1.4 | 1 |
| 133 | Prognostic relevance of FLT3-TKD mutations in AML: the combination matters – an analysis of 3082 patients. Blood, 2008, 111, 2527-2537. | 1.4 | 354 |
| 134 | Rituximab Plus Donor Lymphocyte Infusion (DLI) to Prevent or Treat Relapse for B Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). Blood, 2008, 112, 4304-4304. | 1.4 | 0 |
| 135 | Evaluation of complete disease remission in acute myeloid leukemia. Cancer, 2006, 106, 839-847. | 4.1 | 34 |
| 136 | Implications of NRAS mutations in AML: a study of 2502 patients. Blood, 2006, 107, 3847-3853. | 1.4 | 273 |
| 137 | Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genetics and Cytogenetics, 2005, 157, 53-61. | 1.0 | 44 |
| 138 | Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders. Cancer Genetics and Cytogenetics, 2005, 160, 179-183. | 1.0 | 23 |
| 139 | Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Annals of Hematology, 2005, 84, 250-257. | 1.8 | 57 |
| 140 | Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Annals of Hematology, 2005, 84, 785-791. | 1.8 | 43 |
| 141 | Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia. Leukemia and Lymphoma, 2005, 46, 357-366. | 1.3 | 7 |
| 142 | Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica, 2005, 90, 1502-10. | 3.5 | 55 |